Investor Presentaiton
48
Investor presentation
Full year 2022
Novo NordiskⓇ
A fixed dose combination with GIP entered phase 2 in the second
half of 2021 in people with type 2 diabetes
Phase 2 trial design for semaglutide in combination with GIP
N = ~500
Dose ratio 1:1 Semaglutide QW + GIP QW
Placebo
Dose ratio 1:3 Semaglutide QW + GIP QW
Placebo
Dose ratio 1:5 Semaglutide QW + GIP QW
Placebo
Dose ratio 1:9 Semaglutide + GIP QW
Placebo
GIP QW
Semaglutide QW
Dose escalation
10 weeks
Maintenance period
24 weeks
FU 5
weeks
Inclusion criteria:
•
Age ≥ 18-75 years
•
.
• BMI: 25-39.9 kg/m2
HbA1c: 7.0-10.0%
Diet/exercise + metformin
Type 2 diabetes
Objective:
Compare the effect on glycaemic control and body weight of semaglutide
in combination with GIP vs semaglutide and vs GIP
Primary endpoint:
Change from baseline to week 34 in HbA1c (%-point)
Trial start:
39-week trial was initiated in Q4 2021
T2D: Type 2 diabetes; HbA₁: Hemoglobin A1c; BMI: Body mass index; FU: Follow-up; OAD: Oral anti-diabetic; GIP: Gastric inhibitory peptide; QW: Once-weeklyView entire presentation